Abivax (ABVX) Competitors $77.46 +0.18 (+0.23%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$76.07 -1.39 (-1.79%) As of 08/25/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVX vs. TEVA, SMMT, GMAB, VTRS, ASND, RDY, QGEN, MRNA, BBIO, and VRNAShould you be buying Abivax stock or one of its competitors? The main competitors of Abivax include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Abivax vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Teva Pharmaceutical Industries (NYSE:TEVA) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Is TEVA or ABVX more profitable? Abivax has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Abivax's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% Abivax N/A N/A N/A Which has preferable earnings and valuation, TEVA or ABVX? Abivax has lower revenue, but higher earnings than Teva Pharmaceutical Industries. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.26-$1.64B-$0.16-113.38AbivaxN/AN/A-$190.71MN/AN/A Does the media prefer TEVA or ABVX? In the previous week, Teva Pharmaceutical Industries had 11 more articles in the media than Abivax. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 3 mentions for Abivax. Abivax's average media sentiment score of 1.62 beat Teva Pharmaceutical Industries' score of 1.43 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer TEVA or ABVX? Teva Pharmaceutical Industries currently has a consensus target price of $24.71, indicating a potential upside of 36.24%. Abivax has a consensus target price of $92.33, indicating a potential upside of 19.20%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Abivax 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Do institutionals and insiders have more ownership in TEVA or ABVX? 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, TEVA or ABVX? Teva Pharmaceutical Industries has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Abivax has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. SummaryTeva Pharmaceutical Industries beats Abivax on 10 of the 14 factors compared between the two stocks. Get Abivax News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVX vs. The Competition Export to ExcelMetricAbivaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.84B$3.12B$5.82B$9.74BDividend YieldN/A2.24%4.40%4.08%P/E RatioN/A20.6430.1425.84Price / SalesN/A351.71435.13105.64Price / CashN/A43.2325.7828.79Price / Book112.269.649.425.99Net Income-$190.71M-$54.08M$3.27B$265.29M7 Day Performance12.33%5.58%3.64%4.07%1 Month Performance16.50%4.11%3.52%0.93%1 Year Performance566.04%6.70%29.95%18.21% Abivax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVXAbivax2.7467 of 5 stars$77.46+0.2%$92.33+19.2%+567.8%$5.84BN/A0.0061Positive NewsTEVATeva Pharmaceutical Industries3.2364 of 5 stars$18.08+1.2%$24.71+36.7%-2.3%$20.48B$16.63B-113.0036,830Positive NewsSMMTSummit Therapeutics2.3773 of 5 stars$26.29-1.5%$35.00+33.1%+100.8%$19.83B$700K-26.03110GMABGenmab A/S3.6966 of 5 stars$23.42+0.5%$37.60+60.5%-11.1%$14.95B$3.12B11.772,682VTRSViatris1.8687 of 5 stars$10.63+0.2%$10.40-2.2%-10.3%$12.37B$14.74B-3.6732,000Ex-DividendAnalyst UpgradeASNDAscendis Pharma A/S3.4112 of 5 stars$194.08-2.1%$242.93+25.2%+36.3%$12.13B$490.75M-37.611,017RDYDr. Reddy's Laboratories3.0857 of 5 stars$14.26+0.2%$16.95+18.9%-12.0%$11.87B$3.81B21.6027,811News CoveragePositive NewsQGENQIAGEN3.7963 of 5 stars$48.66-1.4%$49.69+2.1%+8.7%$10.97B$1.98B28.755,765News CoveragePositive NewsMRNAModerna4.6832 of 5 stars$28.09+0.2%$43.59+55.2%-69.3%$10.90B$3.24B-3.735,800Analyst ForecastBBIOBridgeBio Pharma4.5973 of 5 stars$49.02-4.5%$61.35+25.2%+86.8%$9.81B$221.90M-11.99400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.3471 of 5 stars$105.79+0.5%$109.00+3.0%+292.9%$8.96B$42.28M-106.8630Positive News Related Companies and Tools Related Companies TEVA Competitors SMMT Competitors GMAB Competitors VTRS Competitors ASND Competitors RDY Competitors QGEN Competitors MRNA Competitors BBIO Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access